Amvuttra (vutrisiran) 25mg injection
Condition : New
0
From UAE
To United States
in 5-10 days
Description
Amvuttra (Vutrisiran) is an injectable medication used to treat hereditary transthyretin-mediated amyloidosis (hATTR) in adults. This rare genetic disorder causes amyloid protein to build up in the body, leading to nerve and organ damage. Vutrisiran is a small interfering RNA (siRNA) designed to reduce the production of transthyretin (TTR) protein, thereby slowing disease progression. Administered subcutaneously every three months, Amvuttra offers a new treatment option for patients with this debilitating condition.
How It Works
Vutrisiran works by utilizing a mechanism known as RNA interference (RNAi), a natural process that cells use to silence specific genes. In hATTR, mutations in the TTR gene lead to misfolded TTR proteins that form amyloid deposits. Vutrisiran is a synthetic small interfering RNA that targets and degrades the messenger RNA (mRNA) responsible for TTR protein production in the liver. By reducing TTR levels, Amvuttra helps to decrease amyloid formation and slow the progression of symptoms associated with the disease.Side Effects
While Amvuttra is generally well-tolerated, some patients may experience side effects. Common side effects include:- Injection site reactions (redness, swelling, pain)
- Upper respiratory tract infections
- Headache
- Nausea
- Fatigue
- Hypersensitivity reactions (rash, itching, difficulty breathing)
- Liver enzyme elevation
Indications
Amvuttra is indicated for the treatment of:- Hereditary transthyretin-mediated amyloidosis (hATTR) in adults with polyneuropathy
Contraindications
Amvuttra is contraindicated in patients with:- Known hypersensitivity to vutrisiran or any of its excipients
- Severe hepatic impairment
- Pregnancy and breastfeeding unless clearly needed
Price in Different Countries
Country | Price (per 25 mg Injection) | References |
---|---|---|
United States | $450,000 per year | GoodRx Amvuttra Price |
United Kingdom | £327,000 per year | NHS Amvuttra Price |
Canada | $430,000 CAD per year | Canadian Pharmacy Amvuttra Price |
Australia | $460,000 AUD per year | PBS Amvuttra Price |
India | ₹31,500,000 per year | 1mg Amvuttra Price |
Top 5 Global Brands
The top five global brands for similar therapies include:- Onpattro (Patisiran) – Alnylam Pharmaceuticals: Another RNAi therapy for hATTR, Onpattro was the first approved treatment in this class.
- Tegsedi (Inotersen) – Akcea Therapeutics: An antisense oligonucleotide therapy for treating hATTR with polyneuropathy.
- Vyndaqel (Tafamidis) – Pfizer: An oral TTR stabilizer used to treat transthyretin amyloidosis with cardiomyopathy.
- Vyndamax (Tafamidis) – Pfizer: Similar to Vyndaqel but in a different formulation, Vyndamax is used for treating hATTR.
- Alnylam (Vutrisiran) – Alnylam Pharmaceuticals: Known for developing RNAi therapeutics, Alnylam has a robust pipeline for treating genetic disorders.
Related products
-
Uncategorized
Ivermectin: An Effective Antiparasitic Drug for Various Infections
Rated 0 out of 5Get Price